Summary of Recent Deal Activities
- PDF / 131,557 Bytes
- 15 Pages / 611 x 792 pts Page_size
- 39 Downloads / 194 Views
TECHNOLOGY DEALS
© 2004 Adis Data Information BV. All rights reserved.
Summary of Recent Deal Activities Drug Discovery Technologies
Companies
Type of deal
Details
4SC, Mutabilis
R&D agreement
4SC and Mutabilis have signed a research partnership agreement. This partnership aims to identify new molecules as a basis for drug discovery against an undisclosed target provided by Mutabilis. 4SC will use its proprietary virtual high-throughput screening technology 4Scan to screen a database of 4.6 million small organic molecules in order to identify new active compounds that bind to the specific target. Mutabilis will then receive a selection of best ranked molecules for biological testing and further evaluation. In return, 4SC receives undisclosed research funding and will be eligible for milestone payments.
Abbott Laboratories, Compound Therapeutics
Licensing agreement
Compound Therapeutics has granted Abbott Laboratories nonexclusive rights to use the company’s PROfusion technology and certain antibody libraries. PROfusion is an in vitro display technology for the selection and rapid optimisation of high-affinity antibodies and other binding proteins. Under the terms of the agreement, Abbott receives the right to use the licensed technology and libraries for purposes of drug-discovery research directed to the generation of highly potent leads for development and commercialisation of human antibody products. Compound Therapeutics will receive an upfront payment, milestone payments contingent upon meeting specified clinical and commercial objectives, and potential royalty payments related to therapeutic antibody products that may result from the license agreement with Abbott. Compound Therapeutics will provide training and support in the use of PROfusion technology, as well as reagents and human antibody libraries useful to practice the PROfusion technology.
Affymetrix
R&D agreement
Affymetrix and the Broad Institute of Massachussets Institute of Technology and Harvard are collaborating on three landmark research projects. Scientists at the Broad Institute will use the company’s new GeneChip High-Throughput (HT) system to perform pioneering research projects in RNA expression analysis, SNP genotyping and DNA resequencing. The scale, depth and precision of these studies is unprecedented and will enable scientists to perform research that just a year ago was virtually impossible. The Broad Institute plans to use the GeneChip HT system to undertake large-scale genomic and genetics projects, including genome-wide SNP association studies to understand the genetics of complex disease, genome-wide RNA expression analyses to discover the molecular signatures of disease and drug response, and large-scale DNA resequencing for genetic studies of cancer.
Alnylam Pharmaceuticals, Isis Pharmaceuticals
Licensing agreement
Alnylam Pharmaceuticals and Isis Pharmaceuticals have co-exclusively licensed certain core intellectual property relating to all therapeutic uses of microRNA from the Max Planck Society. Under the ter
Data Loading...
